US 12,110,533 B2
Stabilisation and isolation of extracellular nucleic acids
Martin Horlitz, Hilden (DE); Annabelle Schubert, Hilden (DE); and Markus Sprenger-Haussels, Hilden (DE)
Assigned to QIAGEN GmbH, Hilden (DE)
Filed by Qiagen GmbH, Hilden (DE)
Filed on Apr. 29, 2021, as Appl. No. 17/244,268.
Application 17/244,268 is a division of application No. 16/203,307, filed on Nov. 28, 2018, granted, now 11,021,733.
Application 16/203,307 is a continuation of application No. 14/347,051, abandoned, previously published as PCT/EP2012/068892, filed on Sep. 25, 2012.
Claims priority of provisional application 61/539,245, filed on Sep. 26, 2011.
Claims priority of application No. 11182819 (EP), filed on Sep. 26, 2011.
Prior Publication US 2022/0017944 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12N 15/10 (2006.01); C12Q 1/6806 (2018.01)
CPC C12Q 1/68 (2013.01) [C12N 15/1003 (2013.01); C12Q 1/6806 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A composition, comprising:
(a) at least one caspase inhibitor, wherein the at least one caspase inhibitor is a pancaspase inhibitor,
(b) at least one compound according to formula 1,

OG Complex Work Unit Chemistry
wherein R1 is a hydrogen residue or an alkyl residue, R2 and R3 are identical or different hydrocarbon residues with a length of the carbon chain of 1-20 atoms arranged in a linear or branched manner, and R4 is an oxygen residue, and wherein the at least one compound according to formula 1 is a N,N-dialkyl-carboxylic acid amide, and
(c) at least one chelating agent, wherein the at least one chelating agent is EDTA, wherein the composition is capable of stabilizing an extracellular nucleic acid population in a cell-containing biological sample.